Cimzia Treatment for Seronegative RA with MTX Inadequate Response

Clinical Evidence and Guideline Recommendations

The American College of Rheumatology recommends methotrexate (MTX) optimization before biologic initiation, with a dose of 20-30 mg/week, which this patient has reached at 25 mg weekly 1, 2
Guidelines specify that parenteral administration of MTX should be considered in cases of inadequate clinical response to oral MTX due to higher bioavailability and potentially fewer gastrointestinal side effects 1, 2
Multinational evidence-based recommendations support the use of MTX as the anchor for combination therapy with biologics when MTX monotherapy does not achieve disease control 4, 3
The European League Against Rheumatism recommends anti-TNF biologics, including certolizumab pegol, as established standard therapy for RA patients with inadequate response to MTX 5

Certolizumab pegol is one of five FDA-approved anti-TNF agents for RA and has equivalent standing as standard of care compared to other anti-TNF biologics 5
The patient should be monitored for signs and symptoms of infection during and after treatment, including tuberculosis screening prior to initiation, as recommended by the Centers for Disease Control and Prevention 6

Validated disease activity measures, such as DAS28, CDAI, or RAPID3 scores, should be used to quantify moderate-to-severe disease activity, as recommended by the American College of Rheumatology 6
Confirmation that the patient will resume MTX 25 mg weekly concurrently with Cimzia is necessary, as combination therapy is superior to monotherapy, according to the European League Against Rheumatism 4, 3